Marie Kim Wium-Andersen1, David Dynnes Ørsted2, Børge Grønne Nordestgaard3. 1. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark. 2. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark. 3. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark Department of Clinical Biochemistry, Herlev Hospital, Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark Boerge.Nordestgaard@regionh.dk.
Abstract
BACKGROUND: Tobacco smoking is more common among patients with schizophrenia and depression than among healthy individuals. We tested the hypothesis that high tobacco smoking intensity is causally associated with antipsychotic medication use, schizophrenia, antidepressant medication use and/or depression in the general population, and compared results with those for chronic obstructive pulmonary disease. METHODS: We used self-reported smoking intensity in cigarettes/day and a polymorphism in the CHRNA3 gene cluster (rs1051730) associated with smoking intensity, on 63,296 20-100-year-old individuals from the Danish general population; 23,282 were never-smokers and 40,014 ever-smokers. For schizophrenia, we compared our results with those in the Psychiatric Genomics Consortium. RESULTS: In smokers, heterozygotes (CT) and homozygotes (TT) for rs1051730 genotype had higher smoking intensity compared with non-carriers (CC). Furthermore, in ever-smokers homozygotes had increased risk of antipsychotic medication with an odds ratio (OR) of 1.16 [95% confidence interval (CI) 1.02-1.31] compared with non-carriers, whereas in never-smokers the corresponding OR was 1.07 (0.87-1.31) (P-interaction: 0.60). Correspondingly, ORs were 1.60 (0.74-3.47) and 1.02 (0.11-9.10) for schizophrenia (P-interaction: 0.85), 1.02 (0.93-1.13) and 0.99 (0.85-1.15) for antidepressant medication (P-interaction: 0.87), 0.85 (0.66-1.10) and 1.26 (0.87-1.83) for depression (P-interaction: 0.30) and 1.31 (1.16-1.47) and 0.89 (0.58-1.36) for chronic obstructive pulmonary disease (P-interaction: 0.16). Odds ratios per rs1051730 allele for schizophrenia and antipsychotic medication use in ever-smokers in the general population were 1.22 (95% CI: 0.84-1.79) and 1.06 (1.00-1.12). In the Psychiatric Genomics Consortium, the corresponding OR for schizophrenia was 1.06 (1.04-1.08) in ever- and never-smokers combined. CONCLUSION: Our data suggest that tobacco smoking could influence the development of psychotic conditions causally, whereas an influence on depression seems unlikely.
BACKGROUND:Tobacco smoking is more common among patients with schizophrenia and depression than among healthy individuals. We tested the hypothesis that high tobacco smoking intensity is causally associated with antipsychotic medication use, schizophrenia, antidepressant medication use and/or depression in the general population, and compared results with those for chronic obstructive pulmonary disease. METHODS: We used self-reported smoking intensity in cigarettes/day and a polymorphism in the CHRNA3 gene cluster (rs1051730) associated with smoking intensity, on 63,296 20-100-year-old individuals from the Danish general population; 23,282 were never-smokers and 40,014 ever-smokers. For schizophrenia, we compared our results with those in the Psychiatric Genomics Consortium. RESULTS: In smokers, heterozygotes (CT) and homozygotes (TT) for rs1051730 genotype had higher smoking intensity compared with non-carriers (CC). Furthermore, in ever-smokers homozygotes had increased risk of antipsychotic medication with an odds ratio (OR) of 1.16 [95% confidence interval (CI) 1.02-1.31] compared with non-carriers, whereas in never-smokers the corresponding OR was 1.07 (0.87-1.31) (P-interaction: 0.60). Correspondingly, ORs were 1.60 (0.74-3.47) and 1.02 (0.11-9.10) for schizophrenia (P-interaction: 0.85), 1.02 (0.93-1.13) and 0.99 (0.85-1.15) for antidepressant medication (P-interaction: 0.87), 0.85 (0.66-1.10) and 1.26 (0.87-1.83) for depression (P-interaction: 0.30) and 1.31 (1.16-1.47) and 0.89 (0.58-1.36) for chronic obstructive pulmonary disease (P-interaction: 0.16). Odds ratios per rs1051730 allele for schizophrenia and antipsychotic medication use in ever-smokers in the general population were 1.22 (95% CI: 0.84-1.79) and 1.06 (1.00-1.12). In the Psychiatric Genomics Consortium, the corresponding OR for schizophrenia was 1.06 (1.04-1.08) in ever- and never-smokers combined. CONCLUSION: Our data suggest that tobacco smoking could influence the development of psychotic conditions causally, whereas an influence on depression seems unlikely.
Authors: Sarah M Hartz; Amy C Horton; Dana B Hancock; Timothy B Baker; Neil E Caporaso; Li-Shiun Chen; John E Hokanson; Sharon M Lutz; Mary L Marazita; Daniel W McNeil; Carlos N Pato; Michele T Pato; Eric O Johnson; Laura J Bierut Journal: Schizophr Res Date: 2017-03-08 Impact factor: 4.939
Authors: Cinzia Cameli; Elena Bacchelli; Maria De Paola; Giuliano Giucastro; Stefano Cifiello; Ginetta Collo; Maria Michela Cainazzo; Luigi Alberto Pini; Elena Maestrini; Michele Zoli Journal: Eur J Hum Genet Date: 2018-08-08 Impact factor: 4.246
Authors: Joseph Firth; Marco Solmi; Robyn E Wootton; Davy Vancampfort; Felipe B Schuch; Erin Hoare; Simon Gilbody; John Torous; Scott B Teasdale; Sarah E Jackson; Lee Smith; Melissa Eaton; Felice N Jacka; Nicola Veronese; Wolfgang Marx; Garcia Ashdown-Franks; Dan Siskind; Jerome Sarris; Simon Rosenbaum; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2020-10 Impact factor: 49.548
Authors: David M Howard; Mark J Adams; Toni-Kim Clarke; Jonathan D Hafferty; Jude Gibson; Masoud Shirali; Jonathan R I Coleman; Saskia P Hagenaars; Joey Ward; Eleanor M Wigmore; Clara Alloza; Xueyi Shen; Miruna C Barbu; Eileen Y Xu; Heather C Whalley; Riccardo E Marioni; David J Porteous; Gail Davies; Ian J Deary; Gibran Hemani; Klaus Berger; Henning Teismann; Rajesh Rawal; Volker Arolt; Bernhard T Baune; Udo Dannlowski; Katharina Domschke; Chao Tian; David A Hinds; Maciej Trzaskowski; Enda M Byrne; Stephan Ripke; Daniel J Smith; Patrick F Sullivan; Naomi R Wray; Gerome Breen; Cathryn M Lewis; Andrew M McIntosh Journal: Nat Neurosci Date: 2019-02-04 Impact factor: 28.771
Authors: Marcus R Munafò; Sara Larsson Lönn; Jan Sundquist; Kristina Sundquist; Kenneth Kendler Journal: Drug Alcohol Depend Date: 2016-05-06 Impact factor: 4.492
Authors: Suzanne H Gage; George Davey Smith; Jennifer J Ware; Jonathan Flint; Marcus R Munafò Journal: PLoS Genet Date: 2016-02-11 Impact factor: 5.917
Authors: Panagiotis Georgiadis; Dennie G Hebels; Ioannis Valavanis; Irene Liampa; Ingvar A Bergdahl; Anders Johansson; Domenico Palli; Marc Chadeau-Hyam; Aristotelis Chatziioannou; Danyel G J Jennen; Julian Krauskopf; Marlon J Jetten; Jos C S Kleinjans; Paolo Vineis; Soterios A Kyrtopoulos Journal: Sci Rep Date: 2016-02-03 Impact factor: 4.379